Enzon Pharmaceuticals, Inc. ENZN
We take great care to ensure that the data presented and summarized in this overview for ENZON PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ENZN
Top Purchases
Top Sells
About ENZN
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
Insider Transactions at ENZN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 16
2023
|
Randolph C Read Director |
BUY
Open market or private purchase
|
Direct |
84,550
+29.71%
|
$0
$0.14 P/Share
|
|
Jun 14
2023
|
Randolph C Read Director |
BUY
Open market or private purchase
|
Direct |
15,000
+11.5%
|
$0
$0.13 P/Share
|
|
Aug 13
2021
|
Jonathan Couchman > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
107,500
-7.62%
|
$0
$0.39 P/Share
|
|
Nov 18
2020
|
Randolph C Read Director |
BUY
Open market or private purchase
|
Direct |
50,000
+33.23%
|
$0
$0.16 P/Share
|
|
Nov 16
2020
|
Randolph C Read Director |
BUY
Open market or private purchase
|
Direct |
50,450
+50.0%
|
$0
$0.15 P/Share
|
|
Nov 13
2020
|
Jordan Bleznick Director |
BUY
Open market or private purchase
|
Direct |
100,000
+50.0%
|
$0
$0.15 P/Share
|
|
Oct 09
2020
|
Icahn Carl C > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
39,277
+50.0%
|
-
|
|
Oct 09
2020
|
Icahn Carl C > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
29,457,750
+44.96%
|
-
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders